<DOC>
	<DOC>NCT00312156</DOC>
	<brief_summary>The trial is conducted in Europe and Middle East. The aim of the trial is to compare the use of Insulin Detemir once or twice daily combined with mealtime Insulin Aspart against that of NPH Insulin once or twice daily combined with mealtime Insulin Aspart. The trial involves children and adolescents with Type 1 Diabetes.</brief_summary>
	<brief_title>Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 diabetes for at least 12 months Informed consent obtained BMI: 67 years: less than or equal to 19 kg/m2, 89 years: less than or equal to 20 kg/m2, 1011 years: less than or equal to 22 kg/m2, 1213 years: less than or equal to 24 kg/m2 and 1417 years: less than or equal to 27 kg/m2. HbA1c equal to or less than 12.0% Proliferate retinopathy or maculopathy Total daily insulin dose greater than 2.00 IU/kg Any condition or disease that rule out trial participation according to the judgement of the investigator. Mental incapacity, unwillingness or language barriers precluding understanding or cooperation. A lifestyle incompatible with trial participation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>